Mifsud Judith-Marie, Pellegrini Livia, Cozzolino Mauro
IVIRMA Global Research Alliance, IVIRMA Roma, 00169 Rome, Italy.
IVIRMA Global Research Alliance, IVI Foundation, Instituto de Investigación Sanitaria La Fe (IIS La Fe), 46026 Valencia, Spain.
J Clin Med. 2023 Oct 26;12(21):6767. doi: 10.3390/jcm12216767.
Ovarian endometriosis is a gynecological condition that is closely associated with infertility-from its pathogenesis to treatment modalities, this condition presents a challenge both for patients and clinicians alike when seeking conception, due to low AMH levels, peritoneal inflammation, and the inadvertent removal of healthy ovarian parenchyma at surgery. In fact, around half of endometriosis patients seeking fertility require tertiary-level assisted reproduction techniques to achieve a live birth. Oocyte cryopreservation, a procedure initially designed for oncology patients, has emerged over recent years as a very promising treatment strategy for patients who have been diagnosed with ovarian endometriosis in order to preserve their fertility and obtain a live birth at a later stage in their lives. Counseling patients about oocyte preservation techniques at an early stage in the diagnosis, ideally before the age of 35 and especially prior to any surgical treatment, provides an excellent opportunity to discuss future fertility and the benefits associated with oocyte cryopreservation.
卵巢子宫内膜异位症是一种与不孕症密切相关的妇科疾病——从其发病机制到治疗方式,由于抗穆勒氏管激素(AMH)水平低、腹膜炎症以及手术中意外切除健康的卵巢实质,这种疾病在患者和临床医生寻求受孕时都构成了挑战。事实上,约一半寻求生育的子宫内膜异位症患者需要三级辅助生殖技术才能实现活产。卵母细胞冷冻保存最初是为肿瘤患者设计的一种程序,近年来已成为一种非常有前景的治疗策略,适用于被诊断患有卵巢子宫内膜异位症的患者,以便保留其生育能力并在其生命后期实现活产。在诊断早期,理想情况下在35岁之前,尤其是在任何手术治疗之前,为患者提供有关卵母细胞保存技术的咨询,这为讨论未来生育能力以及与卵母细胞冷冻保存相关的益处提供了绝佳机会。